Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Liraglutide
100%
Type 2 Diabetes Prevention
100%
Insulin Degludec
100%
Fixed-ratio Combination
100%
Type 2 Diabetes Mellitus (T2DM)
60%
Glycemic Control
40%
Safety Profile
40%
Weight Gain
20%
Patient Demographics
20%
A1 Receptor
20%
Adverse Effects
20%
Hypoglycemia
20%
Insulin Therapy
20%
Once-daily
20%
Type 2 Diabetic Patients
20%
Receptor Agonist
20%
Cardiovascular Outcome Trials
20%
Glucagon-like
20%
New Therapies
20%
Progressive Disease
20%
Insulin Dose
20%
Diabetes Complications
20%
Expert Opinion
20%
Additive Effect
20%
Area Cover
20%
Increasing Prevalence
20%
Phase III Clinical Trial
20%
Gastrointestinal Side Effects
20%
Increased Safety
20%
Clinical Program
20%
Efficacy Profile
20%
Titration
20%
Mono-component
20%
Glucagon-like peptide-1 Receptor (GLP-1R)
20%
Co-formulation
20%
Stepwise Addition
20%
IDegLira
20%
Individual Agent
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Liraglutide
100%
Insulin Degludec
100%
Disease
16%
Adverse Event
16%
Hypoglycemia
16%
Prevalence
16%
Clinical Trial
16%
Diabetic Complication
16%
Glucagon Like Peptide 1 Receptor Agonist
16%
Gastrointestinal Symptom
16%
Insulin Degludec Plus Liraglutide
16%